Logo Image
Opinion|Videos|September 7, 2026

Bringing CAR T-Cell Therapy Into Community Cancer Centers

Dr. Porter distinguishes community-based CAR T-cell therapy from non-accredited care, describing why extending treatment beyond academic centers demands the same rigorous standards patients already expect.

Episodes in this series

"Bringing CAR T-Cell Therapy Into Community Cancer Centers" takes up the question of what's really driving interest in community-based CAR T-cell therapy access.

Dr. Porter opens by separating two things that often get conflated: doing CAR T-cell therapy in the community and doing it at a non-FACT-accredited site. Most community centers simply are not yet accredited, he explains, so the two categories overlap without being the same goal. The actual interest, he stresses, is expanding access geographically, not avoiding accreditation.

He grounds this in the field's longer history with bone marrow transplant, where access gaps have persisted for years despite many initiatives. Very few of those efforts, he says, meaningfully moved the needle, and CAR T-cell therapy faces the same pattern. Roughly two to three years ago, Dr. Porter's program chose a different approach: rather than repeat transplant-era initiatives, they moved the therapy itself to where patients live. Like many emerging community programs, their sites initially lacked FACT accreditation, again reflecting timing rather than intent to bypass standards.

Dr. Porter emphasizes that community sites still must match the quality of experienced, established treatment centers. He credits FACT with recognizing this need and redesigning standards, originally built for academic bone marrow transplant programs, to be more attainable for community sites without lowering the bar. He believes community centers can realistically meet the large majority of FACT's requirements, and that accreditation gives them both a pathway and a way to maintain quality over time.

In his experience, community centers are motivated to demonstrate high standards and would welcome accreditation frameworks that are manageable, accessible, and appropriately scaled to the CAR T-cell therapy episode of care. Dr. Porter closes by describing FACT as a resource community sites can lean on, much as it has long served major transplant centers.

The next episode in this series, "The True Cost of Running a Community CAR T-Cell Program," puts a dollar figure on what that infrastructure actually costs to build and maintain.